Correspondence |

Cutaneous Infarction Under IL-12/23 p40 Inhibition: A Cautionary Note

Dan Lipsker, MD, PhD; Virginie Lutz, MD
Arch Dermatol. 2011;147(11):1344-1345. doi:10.1001/archdermatol.2011.318.
Text Size: A A A
Published online


Ustekinumab is a human monoclonal antibody developed by Centocor (now Janssen Biotech Inc, Horsham, Pennsylvania), that binds to the shared p40 protein subunit of human interleukin (IL)-12 and IL-23, thereby preventing interaction with their cell surface IL-12R β1 receptor. This leads to a downregulation of interferon- γ and IL-17 synthesis. It is approved in Europe and the United States for the treatment of psoriasis. The PHOENIX 11 and PHOENIX 22 studies that led to approval of the drug showed a correct safety profile, though some statistically nonsignificant serious cardiovascular adverse effects were observed more frequently in patients treated with ustekinumab than in patients in the placebo group.1,3 An earlier study already pointed to a potential excessive risk of myocardial infarction,2 especially in the high-dose group.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure. Necrotic purpura in a patient with psoriasis treated with ustekinumab.




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles